Verition Fund Management LLC Makes New Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Verition Fund Management LLC purchased a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 107,808 shares of the company's stock, valued at approximately $1,533,000.

A number of other institutional investors and hedge funds also recently modified their holdings of TAK. Catalytic Wealth RIA LLC increased its position in shares of Takeda Pharmaceutical by 4.0% in the second quarter. Catalytic Wealth RIA LLC now owns 21,703 shares of the company's stock worth $281,000 after acquiring an additional 841 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock worth $43,000 after purchasing an additional 859 shares in the last quarter. Hexagon Capital Partners LLC raised its stake in Takeda Pharmaceutical by 34.3% during the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company's stock valued at $63,000 after purchasing an additional 1,129 shares during the period. Gallacher Capital Management LLC lifted its holdings in shares of Takeda Pharmaceutical by 7.0% in the second quarter. Gallacher Capital Management LLC now owns 17,365 shares of the company's stock valued at $225,000 after purchasing an additional 1,136 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. boosted its position in shares of Takeda Pharmaceutical by 3.3% in the second quarter. Cutter & CO Brokerage Inc. now owns 41,974 shares of the company's stock worth $543,000 after buying an additional 1,347 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Down 0.5 %

NYSE:TAK traded down $0.07 during trading hours on Friday, hitting $13.73. 960,400 shares of the company's stock traded hands, compared to its average volume of 1,799,622. The stock's fifty day moving average price is $13.88 and its two-hundred day moving average price is $13.86. The firm has a market cap of $43.69 billion, a P/E ratio of 23.67, a P/E/G ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.